文献速递牙体牙髓病

鼻用酮咯酸与布洛芬/对乙酰氨基酚在牙髓痛模型中的随机双盲比较

Ibuprofen and Acetaminophen Versus Intranasal Ketorolac (Sprix) in an Untreated Endodontic Pain Model: A Randomized, Double-blind Investigation.
PubMed 文献 · J Endod · 2019-01-01

结果显示两组在达到50%疼痛缓解、首次疼痛缓解及有意义疼痛缓解的时间上均无显著差异,鼻用酮咯酸可提供非阿片类药物的替代给药途径。

要点

  • 鼻用酮咯酸31.5 mg与对乙酰氨基酚1000 mg/布洛芬600 mg在牙髓痛模型中镇痛效果无显著差异。
  • 两组达到50%疼痛缓解、首次疼痛缓解及有意义疼痛缓解的时间均无显著差异。
  • 鼻用酮咯酸为非阿片类镇痛提供了可自我给药的替代途径。

核心结论

  • 鼻用酮咯酸31.5 mg与对乙酰氨基酚1000 mg/布洛芬600 mg组合在未治疗牙髓痛患者中的镇痛效果无显著差异。

研究设计与样本

  • 患者随机分为两组,分别接受31.5 mg鼻用酮咯酸加安慰剂胶囊,或1000 mg对乙酰氨基酚/600 mg布洛芬胶囊加模拟鼻喷雾。
  • 从给药至240分钟每15分钟用视觉模拟量表记录疼痛评分,并记录达到50%疼痛缓解、首次疼痛缓解及有意义疼痛缓解的时间。

主要发现

  • 给药后120分钟内报告疼痛下降,之后报告疼痛保持相对恒定。
  • 两组在达到50%疼痛缓解、首次疼痛缓解及有意义疼痛缓解的时间上均无显著差异。

临床怎么用

  • 鼻用酮咯酸可作为非阿片类镇痛选择,为临床医生提供额外的给药途径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Previously, ketorolac was available for primary use only via intravenous and intramuscular routes. Its availability in intranasal form offers an alternative route of administration that patients can self-administer. The purpose of this study was to compare the efficacy of intranasal ketorolac (Sprix; Egalet US Inc, Wayne, PA) with a combination of ibuprofen/acetaminophen in an acute pain model of untreated endodontic patients experiencing moderate to severe pain and symptomatic apical periodontitis. METHODS: Seventy patients experiencing moderate to severe pain, a pulpal diagnosis of symptomatic irreversible pulpitis or necrosis, and a periapical diagnosis of symptomatic apical periodontitis participated. Patients were randomly divided into 2 groups and received either 31.5 mg intranasal ketorolac and placebo capsules or 1000 mg acetaminophen/600 mg ibuprofen capsules and a mock nasal spray. Patients recorded perceived pain scores on a visual analog scale every 15 minutes from drug administration up to 240 minutes. The time to 50% pain relief, the first sign of pain relief, and meaningful pain relief were recorded, and the data were analyzed. RESULTS: A decline in reported pain was observed until 120 minutes after dosing, after which reported pain remained relatively constant. There was no significant difference between the 2 groups for the time to 50% pain relief, the first sign of pain relief, or meaningful pain relief. CONCLUSIONS: The effectiveness of intranasal ketorolac was not significantly different from that of a 1000 mg acetaminophen/600 mg ibuprofen combination. Intranasal ketorolac provides a nonnarcotic alternative and an additional route of medication administration to practicing clinicians.

来源:J Endod,查看原文。版权归原作者所有。

引用

  1. Watts K, Balzer S, Drum M, et al. Ibuprofen and Acetaminophen Versus Intranasal Ketorolac (Sprix) in an Untreated Endodontic Pain Model: A Randomized, Double-blind Investigation. J Endod. 2019. PMID: 30711184. doi:10.1016/j.joen.2018.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。